Thermo Fisher Scientific (TMO) announces more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022

Go back to Thermo Fisher Scientific (TMO) announces more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022

Thermo Fisher Scientific Investments Support Rapidly Increasing Bioprocessing Production

March 10, 2021 8:00 AM EST

WALTHAM, Mass., March 10, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company's current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions.

"As the bioprocessing market grows, our customers require a consistent and reliable supply of critical... More